Fig. 3: Primary tumour location and survival in the RAS wild-type per-protocol population.

Left-sided tumours (N = 273): a progression-free survival, b overall survival; right-sided tumours (N = 75): c progression-free survival, d overall survival. Bev bevacizumab, Cet cetuximab.